vimentin antibodies Search Results


antibody production recombinant human vimentin rhvim  (R&D Systems)
93
R&D Systems antibody production recombinant human vimentin rhvim
Antibody Production Recombinant Human Vimentin Rhvim, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody production recombinant human vimentin rhvim/product/R&D Systems
Average 93 stars, based on 1 article reviews
antibody production recombinant human vimentin rhvim - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
anti vimentin  (Bioss)
95
Bioss anti vimentin
Primary antibodies.
Anti Vimentin, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vimentin/product/Bioss
Average 95 stars, based on 1 article reviews
anti vimentin - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
vimentin  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology vimentin
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Vimentin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vimentin/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
vimentin - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
anti phospho vimentin ser56  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc anti phospho vimentin ser56
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Anti Phospho Vimentin Ser56, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho vimentin ser56/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
anti phospho vimentin ser56 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
monoclonal mouse antibody  (Valiant Co Ltd)
90
Valiant Co Ltd monoclonal mouse antibody
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Monoclonal Mouse Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal mouse antibody/product/Valiant Co Ltd
Average 90 stars, based on 1 article reviews
monoclonal mouse antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
vimentin  (Proteintech)
96
Proteintech vimentin
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Vimentin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vimentin/product/Proteintech
Average 96 stars, based on 1 article reviews
vimentin - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
antitwist  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc antitwist
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Antitwist, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antitwist/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
antitwist - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
vimentin  (Bioss)
94
Bioss vimentin
Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization <t>of</t> <t>E-cadherin</t> (green) and <t>vimentin</t> (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.
Vimentin, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vimentin/product/Bioss
Average 94 stars, based on 1 article reviews
vimentin - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti vimentin antibody  (Proteintech)
96
Proteintech anti vimentin antibody
MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, <t>AKT,</t> <t>N-cadherin,</t> E-cadherin, <t>Vimentin</t> and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.
Anti Vimentin Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vimentin antibody/product/Proteintech
Average 96 stars, based on 1 article reviews
anti vimentin antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
vimentin  (R&D Systems)
93
R&D Systems vimentin
MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, <t>AKT,</t> <t>N-cadherin,</t> E-cadherin, <t>Vimentin</t> and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.
Vimentin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vimentin/product/R&D Systems
Average 93 stars, based on 1 article reviews
vimentin - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
antibodies mouse anti human monoclonal antibody  (Boster Bio)
96
Boster Bio antibodies mouse anti human monoclonal antibody
MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, <t>AKT,</t> <t>N-cadherin,</t> E-cadherin, <t>Vimentin</t> and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.
Antibodies Mouse Anti Human Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies mouse anti human monoclonal antibody/product/Boster Bio
Average 96 stars, based on 1 article reviews
antibodies mouse anti human monoclonal antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
anti vimentin  (R&D Systems)
99
R&D Systems anti vimentin
MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, <t>AKT,</t> <t>N-cadherin,</t> E-cadherin, <t>Vimentin</t> and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.
Anti Vimentin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vimentin/product/R&D Systems
Average 99 stars, based on 1 article reviews
anti vimentin - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Primary antibodies.

Journal: PLoS ONE

Article Title: Isolation of putative stem cells present in human adult olfactory mucosa

doi: 10.1371/journal.pone.0181151

Figure Lengend Snippet: Primary antibodies.

Article Snippet: Anti-Vimentin , Bioss , bs-0756R , Rabbit , 1:300 , .

Techniques:

Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization of E-cadherin (green) and vimentin (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.

Journal: Cancer cell

Article Title: Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

doi: 10.1016/j.ccr.2012.11.014

Figure Lengend Snippet: Figure 4. Activation of NF-kB Is Associated with Cxcl1 and Twist Upregulation in p53-Deficient Invasive Carcinoma (A) GSEA comparing all differentially regulated genes from AOM-induced invasive cancers in Tp53DIEC mice with a data set of NF-kB target genes obtained from microdissected invading human tumor epithelia (Horst et al., 2009). Normalized enrichment score: 1.46; p < 0.0001. (B) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (C–F) Immunohistochemical analysis of activated p-p65 (C), CXCL1 (D), F4/80 (E), and Gr-1 (F) in invasive cancers of AOM-challenged Tp53DIEC mice. Dashed white lines mark the basal membrane. Scale bars represent 50 mm. (G) Immunoblot analysis for the indicated proteins in lysates from invasive cancers from Tp53DIEC mice and noninvasive adenomas from Tp53F/F mice 16 weeks after the first AOM administration. (H) Immunohistochemical analysis of Twist in invasive cancers of AOM-challenged Tp53DIEC mice. The scale bar represents 50 mm. (I) Colocalization of E-cadherin (green) and vimentin (red) in invasive cancer epithelial cells of AOM-challenged Tp53DIEC mice, indicating EMT; nuclei are stained using 40,6-diamidino-2-phenylindole (blue). The scale bar represents 200 mm. (J–M) Representative immunohistochemical analysis of p53 (J and L) and p-p65 (K and M) in human colon cancer samples. Scale bars represent 100 mm. (N) Correlation of p53 staining and p-p65 staining (n = 59; c2 test, p < 0.05). (O) Correlation of p-p65 staining and the presence of lymph node (LN) metastases (n = 59; c2 test, p < 0.02). (P) Relative CD68 mRNA level in human colon cancer patients who were characterized by expression of both p53 and p-p65 (p53+/p-p65+; n = 23) or not (other; n = 30). Data are mean ± SE; *p < 0.05 by t test. (Q and R) Representative immunohistochemical staining of CD68 in human colon cancer patients who were characterized by expression of both p53 and phospho-p65 (Q) or the absence of p53 and phospho-p65 (R). Scale bars represent 100 mm. See also Figure S3.

Article Snippet: Standard immunohistochemical procedures were performed using the following antibodies: b-catenin (Santa Cruz; sc-1496), bromodeoxyuridine (BrdU) (AbD Serotec; MCA 2060), cleaved caspase-3 (Cell Signaling; 9661), CXCL1 (R&DSystems;MAB453), F4/80 (Caltag; MF48000), Gr-1 (eBioscience; 12-5931-82), phospho-Histone H2A.X (Cell Signaling; 2577), E-cadherin (Becton Dickinson; 610182), Twist (Abcam; 49254), vimentin (Santa Cruz; SC-7557), VE-cadherin (Santa Cruz; SC-6458), and occludin (Invitrogen; 711500).

Techniques: Activation Assay, Western Blot, Immunohistochemical staining, Membrane, Staining, Expressing

MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, AKT, N-cadherin, E-cadherin, Vimentin and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.

Journal: Frontiers in Pharmacology

Article Title: Manpixiao Decoction Halted the Malignant Transformation of Precancerous Lesions of Gastric Cancer: From Network Prediction to In-Vivo Verification

doi: 10.3389/fphar.2022.927731

Figure Lengend Snippet: MPX downregulates the EGFR-PI3K-Akt related EMT pathway in PLGC model Rats. (A–B) Protein expression levels of EGFR, PI3K, p-AKT, AKT, N-cadherin, E-cadherin, Vimentin and β-catenin in gastric mucosa detected by western blot. Compared with control group, * p < 0.05, ** p < 0.01, *** p < 0.001; Compared with model group, # p < 0.05, ## p < 0.01.

Article Snippet: The primary antibodies including: Anti-EGFR antibody (#4267, CST), Anti-PI3 Kinase antibody (#67071-1-Ig, Proteintech), Anti-p-AKT antibody (#4060, CST), Anti-AKT antibody (#4691, CST), Anti-N-cadherin antibody (#14215S, CST), Anti-E-cadherin antibody (#60335-1-Ig, Proteintech) Anti-β-Catenin antibody (#610154, CST), Anti-Vimentin antibody (#60330-1-Ig, Proteintech), Anti-GAPDH antibody (#5174, CST).

Techniques: Expressing, Western Blot, Control